Search for a trial

1 results

A MULTICENTER, PHASE 2A, RANDOMIZED,
INVESTIGATOR-BLIND, SUBJECT-BLIND, PARALLEL-GROUP
STUDY TO EVALUATE THE EFFICACY AND SAFETY OF
BIMEKIZUMAB AND CERTOLIZUMAB PEGOL IN SUBJECTS
WITH ACTIVE ANKYLOSING SPONDYLITIS

Approved WMORecruitment stopped

3.1 Primary objectiveThe primary objective of the study is to evaluate the efficacy of bimekizumab administered scQ2W for 12 weeks compared to CZP in the treatment of subjects with active AS.3.2 Secondary objectivesThe secondary objectives of the…

A MULTICENTER, PHASE 2A, RANDOMIZED, INVESTIGATOR-BLIND, SUBJECT-BLIND, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BIMEKIZUMAB AND CERTOLIZUMAB PEGOL IN SUBJECTS WITH ACTIVE ANKYLOSING SPONDYLITIS

A MULTICENTER, PHASE 2A, RANDOMIZED,
INVESTIGATOR-BLIND, SUBJECT-BLIND, PARALLEL-GROUP
STUDY TO EVALUATE THE EFFICACY AND SAFETY OF
BIMEKIZUMAB AND CERTOLIZUMAB PEGOL IN SUBJECTS
WITH ACTIVE ANKYLOSING SPONDYLITIS